Professor Park Dong-soo's team at Bundang Cha Hospital achieves 1,500 cases of prostate cancer brachytherapy surgery
Jul 01, 2024
Cha Medical University Bundang Cha Hospital (Director Yoon Sang-wook) and Professor Park Dong-soo of the Department of Urology (Radioactive Oncology Department Shin Hyun-soo and Professor Lim Jung-ho) achieved 1,500 cases of prostate cancer brachytherapy surgery.
Brachytherapy surgery is a method of treating prostate cancer by inserting radioactive isotopes, and was introduced for the first time in Korea in 2007 by Professor Park Dong-soo's team and has the highest number of surgeries in Korea.
Professor Park's team developed the world's first surgical method that reduced the dose of prostate cancer brachytherapy radioactive isotopes by 15%, and reported long-term results in 2019 to prove the superiority of treatment. It has been evaluated as a groundbreaking technique for prostate cancer surgery because it reduces radioactive side effects while treating cancer and allows removal surgery if recurrence is suspected after treatment.
In brachytherapy, it is very important to accurately insert radioisotope substances into the prostate, which has different shapes for each person. Bundang Cha Hospital is conducting surgery and treatment as a team of urology and radiation oncology to increase the accuracy of brachytherapy. A urologist who is familiar with the anatomy of the prostate and has extensive surgical experience is in charge of the surgery, and a radiologic oncologist who has expertise in radiation safety management checks the proper distribution of therapeutic doses in the prostate and performs high-accuracy surgery. A urologist with deep knowledge of prostate cancer plans treatment plans for postoperative management and treatment follow-up management.
According to the Health Insurance Review and Assessment Service's malignant neoplasm (cancer) treatment data, prostate cancer is the cancer with the largest increase in patients in Korea over the past five years. Prostate cancer increased 39.6% from 96,814 in 2019 to 135,119 in 2023. Early prostate cancer has a 5-year survival rate of 95.2%, which is higher than other cancers, but early diagnosis is important because the 5-year survival rate drops to 44.9% for stage 4 cancer with metastasis.
Professor Park Dong-soo said, "Bundang Cha Hospital is a team of professors from the Department of Urology and Radiation Oncology, and offers the best treatment from patient diagnosis to treatment""We will try to provide more quantitative and qualitative medical services based on the systematic system of prostate cancer surgery and treatment with 1,500 brachytherapy operations that require high-level skills ""
Professor Park Dong-soo and Shin Hyun-soo's team at Bundang Cha Hospital are expanding and implementing the scope of brachytherapy, which is mainly applied in low-risk and intermediate-risk groups for prostate cancer.
In 2013, successful results were reported by predicting and performing procedures on patients who are cured with brachytherapy alone among high-risk groups. In 2019, it is publishing related papers in domestic and international journals, such as developing and reporting the world's first surgery method to reduce the dose of prostate cancer brachytherapy radioactive isotopes. In addition, urology and radiation oncology departments are performing all three standard treatments for prostate cancer internationally through multidisciplinary treatment: extraction surgery (robot surgery), external radiation therapy, and brachytherapy. These three treatments are the standard treatment for prostate cancer, which is being proposed by the U.S. Comprehensive Cancer Network (NCCN) guidelines in 2024.
Brachytherapy surgery is a method of treating prostate cancer by inserting radioactive isotopes, and was introduced for the first time in Korea in 2007 by Professor Park Dong-soo's team and has the highest number of surgeries in Korea.
Professor Park's team developed the world's first surgical method that reduced the dose of prostate cancer brachytherapy radioactive isotopes by 15%, and reported long-term results in 2019 to prove the superiority of treatment. It has been evaluated as a groundbreaking technique for prostate cancer surgery because it reduces radioactive side effects while treating cancer and allows removal surgery if recurrence is suspected after treatment.
In brachytherapy, it is very important to accurately insert radioisotope substances into the prostate, which has different shapes for each person. Bundang Cha Hospital is conducting surgery and treatment as a team of urology and radiation oncology to increase the accuracy of brachytherapy. A urologist who is familiar with the anatomy of the prostate and has extensive surgical experience is in charge of the surgery, and a radiologic oncologist who has expertise in radiation safety management checks the proper distribution of therapeutic doses in the prostate and performs high-accuracy surgery. A urologist with deep knowledge of prostate cancer plans treatment plans for postoperative management and treatment follow-up management.
According to the Health Insurance Review and Assessment Service's malignant neoplasm (cancer) treatment data, prostate cancer is the cancer with the largest increase in patients in Korea over the past five years. Prostate cancer increased 39.6% from 96,814 in 2019 to 135,119 in 2023. Early prostate cancer has a 5-year survival rate of 95.2%, which is higher than other cancers, but early diagnosis is important because the 5-year survival rate drops to 44.9% for stage 4 cancer with metastasis.
Professor Park Dong-soo said, "Bundang Cha Hospital is a team of professors from the Department of Urology and Radiation Oncology, and offers the best treatment from patient diagnosis to treatment""We will try to provide more quantitative and qualitative medical services based on the systematic system of prostate cancer surgery and treatment with 1,500 brachytherapy operations that require high-level skills ""
Professor Park Dong-soo and Shin Hyun-soo's team at Bundang Cha Hospital are expanding and implementing the scope of brachytherapy, which is mainly applied in low-risk and intermediate-risk groups for prostate cancer.
In 2013, successful results were reported by predicting and performing procedures on patients who are cured with brachytherapy alone among high-risk groups. In 2019, it is publishing related papers in domestic and international journals, such as developing and reporting the world's first surgery method to reduce the dose of prostate cancer brachytherapy radioactive isotopes. In addition, urology and radiation oncology departments are performing all three standard treatments for prostate cancer internationally through multidisciplinary treatment: extraction surgery (robot surgery), external radiation therapy, and brachytherapy. These three treatments are the standard treatment for prostate cancer, which is being proposed by the U.S. Comprehensive Cancer Network (NCCN) guidelines in 2024.
|
bellho@sportschosun.com
